- Home
- CBRE vs KLTOW Comparison
CBRE vs KLTOW Comparison
Compare CBRE & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | KLTOW |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7B | N/A |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CBRE | KLTOW |
|---|---|---|
| Price | $164.48 | $0.10 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $177.25 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | N/A |
| Earning Date | 02-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.63 | N/A |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $39,325,000,000.00 | N/A |
| Revenue This Year | $16.26 | N/A |
| Revenue Next Year | $9.61 | N/A |
| P/E Ratio | $40.55 | ★ N/A |
| Revenue Growth | ★ 14.61 | N/A |
| 52 Week Low | $108.45 | N/A |
| 52 Week High | $171.00 | N/A |
Technical Indicators
Market Signals| Indicator | CBRE | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 38.85 |
| Support Level | $159.07 | $0.10 |
| Resistance Level | $165.71 | $0.11 |
| Average True Range (ATR) | 2.56 | 0.02 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 85.22 | 15.38 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.